Exercise as Medicine in Multiple Sclerosis—Time for a Paradigm Shift: Preventive, Symptomatic, and Disease-Modifying Aspects and Perspectives

Current Neurology and Neuroscience Reports, Год журнала: 2019, Номер 19(11)

Опубликована: Ноя. 1, 2019

Язык: Английский

---

Therapeutic Advances in Multiple Sclerosis

Frontiers in Neurology, Год журнала: 2022, Номер 13

Опубликована: Июнь 3, 2022

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes significant disability and healthcare burden. The treatment of MS has evolved over past three decades with development new, high efficacy modifying therapies targeting various mechanisms including immune modulation, cell suppression or depletion enhanced sequestration. Emerging include CNS-penetrant Bruton's tyrosine kinase inhibitors autologous hematopoietic stem transplantation as well aimed at remyelination neuroprotection. Therapy for progressive been more challenging limited current approved agents inactive older patients MS. aim this review to provide a broad overview therapeutic landscape

Язык: Английский

---

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis

Cochrane library, Год журнала: 2024, Номер 2024(6)

Опубликована: Янв. 4, 2024

Язык: Английский

---

Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, Год журнала: 2020, Номер 47(4), С. 437 - 455

Опубликована: Апрель 6, 2020

Abstract: The Canadian Multiple Sclerosis Working Group has updated its treatment optimization recommendations (TORs) on the optimal use of disease-modifying therapies for patients with all forms multiple sclerosis (MS). Recommendations provide guidance initiating effective early in course disease, monitoring response to therapy, and modifying or switching optimize disease control. current TORs also address pediatric MS, progressive MS identification aggressive disease. Newer offer improved efficacy, but have potential safety concerns that must be adequately balanced, notably when sequencing is considered. There are added discussions regarding management pregnancy, future biomarkers consideration as it may prudent stop therapy. These meant used interpreted by neurologists a special interest MS.

Язык: Английский

---

Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry

Frontiers in Neurology, Год журнала: 2021, Номер 12

Опубликована: Июнь 17, 2021

Background: Moderate and high efficacy disease modifying therapies (DMTs) have a profound effect on activity. The current treatment guidelines only recommend DMTs for patients with highly active MS. objective was to examine the impact of initial choice in achieving no evidence activity (NEDA) at year 1 2. Methods: Using real-world population-based registry limited selection bias from southeast Norway, we determined how many achieved NEDA moderate DMTs. Results: 68.0% who started DMT as first drug 52.4% 2 compared 36.0 19.4% drug. odds ratio (OR) drugs 3.9 (95% CI 2.4–6.1, p < 0.001). OR second 2.5 1.7–3.9, 0.001), not significant third Patients medium or risk were significantly more likely achieve therapy Conclusions: Achieving is high-efficacy than therapies, most important. immunomodulatory should be updated ensure early, majority diagnosed

Язык: Английский

---

Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis

Journal of Comparative Effectiveness Research, Год журнала: 2023, Номер 12(7)

Опубликована: Июнь 2, 2023

Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA). Materials & methods: Bayesian NMAs annualised relapse rate (ARR) and time to 3-month 6-month confirmed disability progression (3mCDP 6mCDP) were conducted. Results: For each outcome, three most efficacious treatments versus placebo monoclonal antibody (mAb) therapies: alemtuzumab, ofatumumab, ublituximab ARR; ocrelizumab, ofatumumab 3mCDP; natalizumab, either ocrelizumab or (depending on CDP definition used included trials) 6mCDP. Conclusion: The DMTs RMS mAb therapies. Of therapies, only ranked among (for ARR).

Язык: Английский

---

Withametelin, a novel phytosterol, alleviates neurological symptoms in EAE mouse model of multiple sclerosis via modulation of Nrf2/HO-1 and TLR4/NF-κB signaling

Neurochemistry International, Год журнала: 2021, Номер 151, С. 105211 - 105211

Опубликована: Окт. 21, 2021

Язык: Английский

---

Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis

Multiple Sclerosis and Related Disorders, Год журнала: 2023, Номер 71, С. 104581 - 104581

Опубликована: Фев. 16, 2023

Язык: Английский

---

Associations between diet and disease progression and symptomatology in multiple sclerosis: A systematic review of observational studies

Multiple Sclerosis and Related Disorders, Год журнала: 2024, Номер 87, С. 105636 - 105636

Опубликована: Апрель 17, 2024

Язык: Английский

---

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis

JAMA Neurology, Год журнала: 2020, Номер 78(1), С. 48 - 48

Опубликована: Авг. 24, 2020

Doses of fingolimod lower than 0.5 mg per day were not investigated during the clinical development program. Whether doses might retain efficacy with fewer safety risks remains unknown.

Язык: Английский

---